Phaseline

Companies › Sunshine Lake Pharma

Sunshine Lake Pharma: clinical trials, targets and expected readouts

10 active drug programs in 13 registered trials: 7 Phase 1, 3 Phase 3, 3 Phase 2; Oncology, Other, Respiratory, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HEC585–Phase 3Idiopathic Pulmonary Fibrosis (IPF); Idiopathic Pulmonary Fibrosis; Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)Dec 2026
Larotinib
EGFR tyrosine kinase inhibitor
EGFRPhase 3Esophageal CancerAug 2027
Clifutinib Besylate (HEC73543)
FLT3-ITD inhibitor
FLT3Phase 3Leukemia, Acute Myeloid (AML); Acute Myeloid Leukemia, AdultNov 2027
Mitizodone Phosphate tablets
unclear mechanism for major depressive disorder
–Phase 2Depressive Disorder, MajorJul 2027
HEC169584–Phase 1Non - Alcoholic SteatohepatitisDec 2026
HEC-007 injection–Phase 1Healthy SubjectsDec 2026
HEC-151 Injection–Phase 1Healthy Adult MaleDec 2026
HECN30227 injection–Phase 1HBV InfectionApr 2027
HEC-921–Phase 1Advanced Malignant Solid TumorsMay 2028
HEC169096–Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05451602HEC169096Phase 1Advanced Solid TumorOncologySep 2025
NCT05060822HEC585Phase 2Idiopathic Pulmonary FibrosisRespiratoryDec 2026
NCT05139719HEC585Phase 2Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)RespiratoryDec 2026
NCT07099118HEC169584Phase 1Non - Alcoholic SteatohepatitisGastroenterologyDec 2026
NCT07102251HEC-007 injectionPhase 1Healthy SubjectsOtherDec 2026
NCT07376200HEC-151 InjectionPhase 1Healthy Adult MaleOtherDec 2026
NCT07771140HECN30227 injectionPhase 1HBV InfectionInfectious diseaseApr 2027
NCT04984512Mitizodone Phosphate tabletsPhase 2Depressive Disorder, MajorPsychiatryJul 2027
NCT04415853LarotinibPhase 3Esophageal CancerOncologyAug 2027
NCT05586074Clifutinib Besylate (HEC73543)Phase 3Leukemia, Acute Myeloid (AML)OncologyNov 2027
NCT05133882Clifutinib Besylate (HEC73543)Phase 1Acute Myeloid Leukemia, AdultOncologyDec 2027
NCT07824934HEC-921Phase 1Advanced Malignant Solid TumorsOncologyMay 2028
NCT07082842HEC585Phase 3Idiopathic Pulmonary Fibrosis (IPF)RespiratoryJan 2031

Targets

FLT3 (1) EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Novartis Daiichi Sankyo Jiangsu HengRui Medicine Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen)

Companies built like this

Jiangsu Alphamab Biopharmaceuticals Nanjing Sanhome Pharmaceutical HC Biopharma Jiangsu Aosaikang Pharmaceutical Jiangsu Hansoh Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.